MCNAMARA DENNIS JOSEPH
No ORCID on file
· 40 papers in corpus
· active 1997-2008
Frequent coauthors
2008
The invention relates to compounds represented by formula I: which are irreversible inhibitors of tyrosine kinazes, to pharmaceutiyal compositions containing the same and to the use thereof in the treatment of cancer, atherosclerosis, reste…
2008
The invention relates to compounds represented by formula I: which are irreversible inhibitors of tyrosine kinazes, to pharmaceutiyal compositions containing the same and to the use thereof in the treatment of cancer, atherosclerosis, reste…
2008
The invention relates to compounds represented by formula I: which are irreversible inhibitors of tyrosine kinazes, to pharmaceutiyal compositions containing the same and to the use thereof in the treatment of cancer, atherosclerosis, reste…
2008
The invention relates to compounds represented by formula I: which are irreversible inhibitors of tyrosine kinazes, to pharmaceutiyal compositions containing the same and to the use thereof in the treatment of cancer, atherosclerosis, reste…
2008
The invention relates to compounds represented by formula I: which are irreversible inhibitors of tyrosine kinazes, to pharmaceutiyal compositions containing the same and to the use thereof in the treatment of cancer, atherosclerosis, reste…
2005
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…
2005
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…
2005
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…
2005
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…
2005
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro- phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylami…
2004
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamid…
2004
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamid…
2004
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamid…
2004
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamid…
2004
Methods and materials for preparing irreversible inhibitors of tyrosine kinases of general Formula (1) are disclosed. Such inhibitors, which include N-[4-)3-chloro-4-floro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamid…
2003
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2003
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2003
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2003
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2003
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2002
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2002
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2002
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2002
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …
2002
The present invention provides compounds that are irreversible inhibitors of tyrosine kinases. Also provided is a method of treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that …